BC Innovations | Jun 20, 2017
Distillery Therapeutics

Other

INDICATION: Genetic disorders Patient sample and mouse studies suggest inhibiting COL6A1 could help treat hyaline fibromatosis syndrome (HFS), which is caused by ANTXR2 mutations. In patients, levels of COL6A1 were higher in HFS skin nodules...
BioCentury | Jan 28, 2013
Emerging Company Profile

MD Pharma AB: Dialing down autophagy

With no approved drugs for congenital muscular dystrophy, patients often die in their teens. MD Pharma AB is developing autophagy inhibitors that could extend and improve quality of life for a subgroup of patients. The...
BC Innovations | Oct 18, 2012
Cover Story

Taking the fat out of cancer

Researchers from The University of Texas Southwestern Medical Center have shown that an antibody targeting endotrophin , a fat cell-derived extracellular protein, reduced growth of breast tumors in mice. 1 The team will next study the...
BC Innovations | Nov 4, 2010
Distillery Therapeutics

Indication: Musculoskeletal disease

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Musculoskeletal disease Muscular dystrophy Collagen type VI a1 (COL6A1); beclin 1 autophagy related (BECN1; beclin1) Studies in human tissue and in mice...
Items per page:
1 - 4 of 4